| Primary Myelofibrosis
Ojjaara vs Inrebic
Side-by-side clinical, coverage, and cost comparison for primary myelofibrosis.Deep comparison between: Ojjaara vs Inrebic with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsInrebic has a higher rate of injection site reactions vs Ojjaara based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Inrebic but not Ojjaara, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ojjaara
Inrebic
At A Glance
Oral
Once daily
JAK1/JAK2 inhibitor
Oral
Once daily
JAK2 inhibitor
Indications
- Primary Myelofibrosis
- Post-polycythemia vera myelofibrosis
- Post-essential thrombocythemia myelofibrosis
- Primary Myelofibrosis
- Post-polycythemia vera myelofibrosis
- Post-essential thrombocythemia myelofibrosis
Dosing
Primary Myelofibrosis, Post-polycythemia vera myelofibrosis, Post-essential thrombocythemia myelofibrosis 200 mg orally once daily with or without food; swallow tablets whole.
Severe hepatic impairment (Child-Pugh Class C) Reduce starting dose to 150 mg orally once daily.
Primary Myelofibrosis, Post-polycythemia vera myelofibrosis, Post-essential thrombocythemia myelofibrosis 400 mg orally once daily with or without food for patients with baseline platelet count >=50 x 10^9/L; thiamine prophylaxis 100 mg orally daily required during treatment.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Thrombocytopenia, diarrhea, hemorrhage, fatigue
Serious Bacterial infection, viral infection, hemorrhage, acute kidney injury, pneumonia, pyrexia, thrombosis, syncope, thrombocytopenia, renal and urinary tract infection
Postmarketing Hypersensitivity, erythema multiforme, toxic epidermal necrolysis
Most common (>=20%) diarrhea, nausea, anemia, vomiting, fatigue, thrombocytopenia, constipation
Serious cardiac failure, anemia, cardiogenic shock
Postmarketing uveitis
Pharmacology
Momelotinib is a JAK1/JAK2 inhibitor that suppresses dysregulated JAK-STAT signaling in myelofibrosis and, via ACVR1 inhibition, reduces hepcidin expression to increase iron availability and red blood cell production.
JAK2-selective oral kinase inhibitor; fedratinib inhibits wild-type and mutationally activated JAK2 and FLT3, reducing STAT3/5 phosphorylation and blocking abnormal signaling associated with myeloproliferative neoplasms.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ojjaara
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
Inrebic
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Ojjaara
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Inrebic
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (2/8)
Humana
Ojjaara
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Inrebic
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Myeloproliferative Neoplasms
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$0
Bristol-Myers Squibb Patient Assistance Foundation (BMSPAF)Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
OjjaaraView full Ojjaara profile
InrebicView full Inrebic profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.